By Daniella Parra
Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with an exclusive option to license a diagnostic platform for central nervous system cancer patients undergoing radiotherapy, the company said.
CNSide is a proprietary assay that quantifies tumor cells in the cerebrospinal fluid of patients with various solid organ carcinomas and suspected leptomeningeal metastases, including breast and lung cancer and melanoma, it said.
Plus Therapeutics reported it will issue $150,000 worth of its common stock to Biocept.
“Use of the CNSide assay has the potential to substantially improve the diagnostic paradigm for patients with solid tumor leptomeningeal disease and could provide valuable information for these patients who have limited treatment options but where a targeted therapy may be beneficial,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology and Medicine at Northwestern University’s Feinberg School of Medicine. “Paired with novel investigational therapeutics such as Plus Therapeutics’ rhenium obisbemeda, the overall clinical management of these challenging patients could be transformed.”
Contact:
Editor@Executives-edge.com
